The tissue Morcellator is a specialised medical device crucial for addressing benign prostate enlargement (BPH) in patients, a condition that affects around 2.5 million men in the UK. Its primary role is to break down sizable masses of prostate tissue efficiently for removal and will be used to treat patients in the Urology Department at Basingstoke Hospital. 

Currently, HHFT faces limitations in treating patients with larger prostates due to longer operating time, which heightens surgical risks such as bleeding. Investing in the Morcellator will allow for safer procedures, whilst also enhancing the capacity to manage a greater volume of patient referrals with enlarged prostates. This will not only expand patient access to care but also significantly reduce theatre time by approximately 20 hours per month at Basingstoke Hospital, facilitating quicker turnaround times for various procedures.